Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer

Nature Reviews Cancer

Volumn 7, Issue 5, 2007, Pages 357-369

  Liby, Karen T ^a   Yore, Mark M ^a   Sporn, Michael B ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; 2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID IMIDAZOLE; 2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID METHYL ESTER; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; ALITRETINOIN; AMIDE; ANTINEOPLASTIC AGENT; ARZOXIFENE; BEXAROTENE; BONE MORPHOGENETIC PROTEIN; CISPLATIN; COLLAGENASE 3; CYCLOOXYGENASE 2; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; NAVELBINE; OLEANOLIC ACID; PACLITAXEL; RETINOIC ACID DERIVATIVE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TRITERPENOID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSOLIC ACID; VTP 194204;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; BREAST CANCER; BRONCHUS MUCOSA; CANCER; CANCER PREVENTION; CANCER THERAPY; CELL FUNCTION; CELL PROTECTION; CHONDROSARCOMA; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; EPIGENETICS; EXPERIMENTAL MOUSE; EXPERIMENTAL NEOPLASM; EXPERIMENTAL RAT; GROWTH INHIBITION; HUMAN; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR BIOLOGY; NONHUMAN; OSTEOSARCOMA CELL; OVARY CARCINOMA; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; T CELL LEUKEMIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; NEOPLASMS; OLEANOLIC ACID; RETINOID X RECEPTORS;

EID: 34247526984     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2129     Document Type: Review

References (170)

1. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
2. Venkatesan, R. N., Bielas, J. H. & Loeb, L. A. Generation of mutator mutants during carcinogenesis. DNA Repair (Amst.) 5, 294-302 (2006).
3. Phillips, D. R., Rasbery, J. M., Bartel, B. & Matsuda, S. P. Biosynthetic diversity in plant triterpene cyclization. Curr. Opin. Plant Biol. 9, 305-314 (2006).
4. Nishino, H. et al. Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds. Cancer Res. 48, 5210-5215 (1988).
5. Huang, M. T. et al. Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res. 54, 701-708 (1994).
6. Dzubak, P. et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nature Prod. Rep. 23, 394-411 (2006).
7. Connolly, J. D. & Hill, R. A. Triterpenoids. Nature Prod. Rep. 22, 487-503 (2005).
8. Honda, T. et al. Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem. 43, 1866-1877 (2000).
9. Honda, T. et al. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem. 43, 4233-4246 (2000). This is a key paper that describes the chemical synthesis of CDDO in great detail.
10. Honda, T. et al. A novel dicyanotriterpenoid, 2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg. Med. Chem. Lett. 12, 1027-1030 (2002).
11. Nathan, C. Points of control in inflammation. Nature 420, 846-852 (2002). An outstanding overview of the inflammatory process. This article is the introduction to an entire series of articles that describe the importance of the inflammatory process in many other diseases.
12. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
13. Balkwill, F., Charles, K. A. & Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217 (2005).
14. Albini, A. & Sporn, M. B. The tumor microenvironment as a target for chemoprevention. Nature Rev. Cancer 7, 139-147 (2007).
15. Honda, T. et al. Design and synthesis of 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg. Med. Chem. Lett. 8, 2711-2714 (1998).
16. Suh, N. et al. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res. 58, 717-723 (1998).
17. Suh, N. et al. A novel synthetic oleanane triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid, with potent differentiating, antiproliferative, and antiinflammatory activity. Cancer Res. 59, 336-341 (1999). The first description of the importance of the biological activity of CDDO.
18. Suh, N. et al. Synthetic triterpenoids enhance transforming growth factor β/smad signaling. Cancer Res. 63, 1371-1376 (2003).
19. Place, A. E. et al. The novel synthetic triterpenoid, CDDO-Imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin. Cancer Res. 9, 2798-2806 (2003).
20. Chauhan, D. et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 103, 3158-3166 (2004).
21. Dinkova-Kostova, A. T. et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc. Natl Acad. Sci. USA 102, 4584-4589 (2005). Shows for the first time the correlation of the antiinflammatory and anti-oxidative activities of an entire series of triterpenoids.
22. Couch, R. D. et al. Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. Bioorg. Med. Chem. Lett. 15, 2215-2219 (2005).
23. Dinkova-Kostova, A. T., Massiah, M. A., Bozak, R. E., Hicks, R. J. & Talalay, P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl Acad. Sci. USA 98, 3404-3409 (2001).
24. Talalay, P., Dinkova-Kostova, A. T. & Holtzclaw, W. D. Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis. Adv. Enzyme Regul. 43, 121-134 (2003).
25. Yu, X. & Kensler, T. Nrf2 as a target for cancer chemoprevention. Mutat. Res. 591, 93-102 (2005).
26. Kobayashi, M. & Yamamoto, M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv. Enzyme Regul. 46, 113-140 (2006).
27. Nguyen, T., Yang, C. S. & Pickett, C. B. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic. Biol. Med. 37, 433-441 (2004).
28. Liby, K. et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 65, 4789-4798 (2005).
29. Lapillonne, H. et al. Activation of peroxisome proliferator-activated receptor γ by a novel synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res. 63, 5926-5939 (2003).
30. Yates, M. S. et al. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-, 12-dioxooleana-1, 9(11)-dien-28-oyl]imidazole. Cancer Res. 66, 2488-2494 (2006). The first report of the use of an SO to prevent cancer.
31. Ito, Y. et al. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol. Pharmacol. 59, 1094-1099 (2001).
32. Ikeda, T. et al. Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid. Mol. Cancer Ther. 3, 39-45 (2004).
33. Ikeda, T., Sporn, M., Honda, T., Gribble, G. W. & Kufe, D. The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res. 63, 5551-5558 (2003).
34. Samudio, I. et al. 2-Cyano-3, 12-dioxooleana-1, 9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J. Biol. Chem. 280, 36273-36282 (2005).
35. Sporn, M. B. & Liby, K. T. Cancer chemoprevention: scientific promise, clinical uncertainty. Nature Clin. Pract. Oncol. 2, 518-525 (2005).
36. Lee, J. M. et al. Nrf2, a multi-organ protector? FASEB J. 19, 1061-1066 (2005).
37. Wang, Y. et al. A synthetic triterpenoid, 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor γ. Mol. Endocrinol. 14, 1550-1556 (2000).
38. Konopleva, M. et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99, 326-335 (2002).
39. Ikeda, T. et al. Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells. Cell Death Differ. 12, 523-531 (2005).
40. Ji, Y. et al. The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. Mol. Cancer Ther. 5, 1452-1458 (2006).
41. Chintharlapalli, S. et al. 2-Cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and-independent pathways. Mol. Pharmacol. 68, 119-128 (2005).
42. Kim, K. B. et al. Identification of a novel synthetic triterpenoid, methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells. Mol. Cancer Ther. 1, 177-184 (2002).
43. Zou, W. et al. c-Jun NH2-terminal kinase-mediated upregulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 64, 7570-7578 (2004).
44. Ray, D. M. et al. The novel triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway. Exp. Hematol. 34, 1202-1211 (2006).
45. Pedersen, I. M. et al. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 100, 2965-2972 (2002).
46. Melichar, B. et al. Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. Gynecol. Oncol. 93, 149-154 (2004).
47. Dragnev, K. H. et al. Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin. Cancer Res. 10, 2570-2577 (2004).
48. Konopleva, M. et al. Synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol. Cancer Ther. 5, 317-328 (2006).
49. Shishodia, S., Sethi, G., Konopleva, M., Andreeff, M. & Aggarwal, B. B. A synthetic triterpenoid, CDDO-Me, inhibits IκBα kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through downregulation of expression of nuclear factor κB-regulated gene products in human leukemic cells. Clin. Cancer Res. 12, 1828-1838 (2006).
50. Vazquez, N. et al. Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation. J. Virol. 79, 4479-4491 (2005).
51. Suh, W. S. et al. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia 17, 2122-2129 (2003).
52. Konopleva, M. et al. The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 19, 1350-1354 (2005).
53. Trachootham, D. et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10, 241-252 (2006).
54. Doroshow, J. H. Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J. Natl Cancer Inst. 98, 223-225 (2006).
55. Schumacker, P. T. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10, 175-176 (2006).
56. Stadheim, T. A., Suh, N., Ganju, N., Sporn, M. B. & Eastman, A. The novel triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. J. Biol. Chem. 277, 16448-16455 (2002).
57. Kim, Y., Suh, N., Sporn, M. & Reed, J. C. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277, 22320-22329 (2002).
58. Hyer, M. L. et al. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 65, 4799-4808 (2005).
59. Zhang, C., Ni, X., Konopleva, M., Andreeff, M. & Duvic, M. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sezary syndrome cells. J. Invest. Dermatol. 123, 380-387 (2004).
60. Yue, P., Zhou, Z., Khuri, F. R. & Sun, S. Y. Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). Cancer Biol. Ther. 5, 492-497 (2006).
61. Ito, Y. et al. The novel triterpenoid 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ. 11, 261-267 (2000).
62. Konopleva, M. et al. The synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid induces caspase-dependent and-independent apoptosis in acute myelogenous leukemia. Cancer Res. 64, 7927-7935 (2004).
63. Inoue, S., Snowden, R. T., Dyer, M. J. & Cohen, G. M. CDDO induces apoptosis via the intrinsic pathway in lymphoid cells. Leukemia 18, 948-952 (2004).
64. Samudio, I. et al. A novel mechanism of action of methyl-2-cyano-3, 12 dioxoolean-1, 9 diene-28-oate: direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis. Mol. Pharmacol. 69, 1182-1193 (2006).
65. Hail, N. Jr, Konopleva, M., Sporn, M., Lotan, R. & Andreeff, M. Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid (CDDO). J. Biol. Chem. 279, 11179-11187 (2004).
66. Liby, K. et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin. Cancer Res. 12, 4288-4293 (2006). Identifies STAT signaling as a crucial target for SO.
67. Yore, M. M., Liby, K. T., Honda, T., Gribble, G. W. & Sporn, M. B. The synthetic triterpenoid, CDDO-Imidazolide blocks NF-κB activation through direct inhibition of IKK. Mol. Cancer Ther. 5, 3239 (2006).
68. Ahmad, R., Raina, D., Meyer, C., Kharbanda, S. & Kufe, D. Triterpenoid CDDO-Me blocks the NF-κB pathway by direct inhibition of IKKβ on Cys-179. J. Biol. Chem. 281, 35764-35769 (2006).
69. Sun, S. Y., Hail, N. Jr. & Lotan, R. Apoptosis as a novel target for cancer chemoprevention. J. Natl Cancer Inst. 96, 662-672 (2004).
70. Reed, J. C. Apoptosis-targeted therapies for cancer. Cancer Cell 3, 17-22 (2003).
71. Finkel, T. Opinion: radical medicine: treating ageing to cure disease. Nature Rev. Mol. Cell Biol. 6, 971-976 (2005).
72. Liby, K. et al. The triterpenoid, CDDO-methyl ester, and the rexinoid, LG100268, synergize in the prevention of mammary tumors in a mouse model of estrogen receptor-negative breast cancer. Fifth Annual AACR International Conference: Frontiers in Cancer Prevention Research. 2006. Boston.
73. Thimmulappa, R. K. et al. Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochem. Biophys. Res. Commun. 351, 883-889 (2006). Shows the striking effects of SO in vivo for the suppression of inflammation.
74. Liby, K. et al. The synthetic triterpenoids, CDDO-methyl ester and CDDO-ethyl amide, prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 67, 2414-2419 (2007).
75. Meyer, C. et al. RTA 402 (CDDO-Me) supresses tumor and treatment induced inflammation, sensitizing tumors to and protecting normal tissue from radiation. Eur. J. Cancer Suppl. 4, 162 (2006).
76. Semple, R. K., Chatterjee, V. K. & O'Rahilly, S. PPAR γ and human metabolic disease. J. Clin. Invest. 116, 581-589 (2006).
77. Lehrke, M. & Lazar, M. A. The many faces of PPARgamma. Cell 123, 993-999 (2005).
78. Karin, M. & Greten, F. R. NF-κB: linking inflammation and immunity to cancer development and progression. Nature Rev. Immunol. 5, 749-759 (2005).
79. Luo, J. L., Kamata, H. & Karin, M. IKK/NF-κB signaling: balancing life and death- a new approach to cancer therapy. J. Clin. Invest. 115, 2625-2632 (2005).
80. Bierie, B. & Moses, H. L. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nature Rev. Cancer 6, 506-520 (2006).
81. Letterio, J. J. TGFβ signaling in T cells: roles in lymphoid and epithelial neoplasia. Oncogene 24, 5701-5712 (2005).
82. Barrios-Rodiles, M. et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307, 1621-1625 (2005).
83. Mix, K. S. et al. Peroxisome proliferator-activated receptor-γ-independent repression of collagenase gene expression by 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid and prostaglandin 15-deoxy-δ(12, 14) J2: a role for Smad signaling. Mol. Pharmacol. 65, 309-318 (2004).
84. Minns, L. A. et al. A novel triterpenoid induces transforming growth factor β production by intraepithelial lymphocytes to prevent ileitis. Gastroenterology 127, 119-126 (2004).
85. Yu, H. & Jove, R. The STATs of cancer - new molecular targets come of age. Nature Rev. Cancer 4, 97-105 (2004).
86. Dauer, D. J. et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 24, 3397-3408 (2005).
87. Kinjyo, I. et al. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-β 1. J. Exp. Med. 203, 1021-1031 (2006).
88. Couch, R. D. et al. 2-cyano-3, 12-dioxooleana-1, 9(11)-diene-28-oic acid disrupts microtubule polymerization: a possible mechanism contributing to apoptosis. Mol. Pharmacol. 69, 1158-1165 (2006).
89. Liu, H., Colavitti, R., Rovira, I. I. & Finkel, T. Redox-dependent transcriptional regulation. Circ. Res. 97, 967-974 (2005).
90. Dinkova-Kostova, A. T. et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl Acad. Sci. USA 99, 11908-11913 (2002).
91. Eggler, A. L., Liu, G., Pezzuto, J. M., van Breemen, R. B. & Mesecar, A. D. Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc. Natl Acad. Sci. USA 102, 10070-10075 (2005).
92. Na, H. K. & Surh, Y. J. Transcriptional regulation via cysteine thiol modification: a novel molecular strategy for chemoprevention and cytoprotection. Mol. Carcinog. 45, 368-380 (2006). Stresses the importance of cysteine residues as targets for chemoprevention of cancer.
93. Mukherjee, S. et al. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 312, 1211-1214 (2006).
94. Kim, S. F., Huri, D. A. & Snyder, S. H. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310, 1966-1970 (2005).
95. Tonks, N. K. Protein tyrosine phosphatases: from genes, to function, to disease. Nature Rev. Mol. Cell Biol. 7, 833-846 (2006).
96. Honda, T. et al. Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oic acid for the isolation of the protein targets. J. Med. Chem. 47, 4923-4932 (2004). A key reference describing the synthesis of biotinylated SO.
97. Janes, K. A. et al. A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 310, 1646-1653 (2005).
98. Nel, A., Xia, T., Madler, L. & Li, N. Toxic potential of materials at the nanolevel. Science 311, 622-627 (2006).
99. Kim, E. H. & Surh, Y. J. 15-Deoxy-δ(12, 14)-prostaglandin J(2) as a potential endogenous regulator of redox-sensitive transcription factors. Biochem. Pharmacol. 72, 1516-1528 (2006).
100. Haridas, V., Arntzen, C. J. & Gutterman, J. U. Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), inhibit activation of nuclear factor-κB by inhibiting both its nuclear localization and ability to bind DNA. Proc. Natl Acad. Sci. USA 98, 11557-11562 (2001).
101. Pisha, E. et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nature Med. 1, 1046-1051 (1995).
102. Yang, H., Chen, D., Cui, Q. C., Yuan, X. & Dou, Q. P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 66, 4758-4765 (2006).
103. Howells, L. M. & Manson, M. M. Prospects for plant-derived chemopreventive agents exhibiting multiple mechanisms of action. Curr. Med. Chem. Anti-Canc. Agents 5, 201-213 (2005).
104. Seong, S. Y. & Matzinger, P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nature Rev. Immunol. 4, 469-478 (2004). A highly provocative and stimulating discussion of the danger hypothesis and the responses of cells to injury.
105. Nes, W. D. (Ed). Isopentenoids and other natural products: evolution and function 255 (American Chemical Society, Washington D. C., USA, 1994).
106. Mangelsdorf, D. J., Ong, E. S., Dyck, J. A. & Evans, R. M. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 345, 224-229 (1990). The original discovery of RXRs.
107. Mangelsdorf, D. J. et al. A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell 66, 555-561 (1991).
108. Heyman, R. A. et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 68, 397-406 (1992).
109. Mukherjee, R. et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386, 407-410 (1997). The word 'rexinoid' is defined here for the first time, and the interaction of RXRs with PPARγ is stressed.
110. Mangelsdorf, D. J. & Evans, R. M. The RXR heterodimers and orphan receptors. Cell 83, 841-850 (1995).
111. Chawla, A., Repa, J. J., Evans, R. M. & Mangelsdorf, D. J. Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870 (2001).
112. Sporn, M. B. & Suh, N. Chemoprevention: an essential approach to controlling cancer. Nature Rev. Cancer 2, 537-543 (2002).
113. Shulman, A. I. & Mangelsdorf, D. J. Retinoid x receptor heterodimers in the metabolic syndrome. N. Engl. J. Med. 353, 604-615 (2005).
114. Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nature Rev. Cancer 4, 891-899 (2004).
115. Sharma, V. et al. Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis. Endocrinology 147, 1438-1451 (2006).
116. Farol, L. T. & Hymes, K. B. Bexarotene: a clinical review. Expert Rev. Anticancer Ther. 4, 180-188 (2004).
117. Dragnev, K. H., Petty, W. J., Ma, Y., Rigas, J. R. & Dmitrovsky, E. Nonclassical retinoids and lung carcinogenesis. Clin. Lung Cancer 6, 237-244 (2005).
118. Lehmann, J. M. et al. Retinoids selective for retinoid X receptor response pathways. Science 258, 1944-1946 (1992). The first synthesis of a rexinoid.
119. Boehm, M. F. et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J. Med. Chem. 37, 2930-2941 (1994).
120. Boehm, M. F. et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J. Med. Chem. 38, 3146-3155 (1995).
121. Vuligonda, V., Thacher, S. M. & Chandraratna, R. A. Enantioselective syntheses of potent retinoid X receptor ligands: differential biological activities of individual antipodes. J. Med. Chem. 44, 2298-2303 (2001). Describes the first synthesis and properties of the rexinoid, AGN 194204.
122. Michellys, P. Y. et al. Novel (2E, 4E, 6Z)-7-(2-alkoxy-3, 5-dialkylbenzene)-3-methylocta-2, 4, 6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes. J. Med. Chem. 46, 2683-2696 (2003).
123. Michellys, P. Y. et al. Design, synthesis, and structure-activity relationship studies of novel 6, 7-locked-[7-(2-alkoxy-3, 5-dialkylbenzene)-3- methylocta]-2, 4, 6-trienoic acids. J. Med. Chem. 46, 4087-4103 (2003).
124. Michellys, P. Y. et al. Design, synthesis and structure-activity relationship of novel RXR-selective modulators. Bioorg. Med. Chem. Lett. 14, 1593-1598 (2004).
125. Haffner, C. D. et al. Structure-based design of potent retinoid X receptor α agonists. J. Med. Chem. 47, 2010-2029 (2004).
126. Leibowitz, M. D. et al. Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes. Endocrinology 147, 1044-1053 (2006).
127. Wu, K. et al. Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Res. Treat. 96, 147-157 (2006).
128. Balasubramanian, S., Chandraratna, R. A. & Eckert, R. L. Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid. Carcinogenesis 25, 1377-1385 (2004).
129. Kong, G. et al. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res. 65, 3462-3469 (2005).
130. Rendi, M. H. et al. The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor β-dependent apoptosis in breast cancer. Cancer Res. 64, 3566-3571 (2004).
131. Dragnev, K. H. et al. Bexarotene and erlotinib for aerodigestive tract cancer. J. Clin. Oncol. 23, 8757-8764 (2005).
132. Kim, H. T. et al. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 66, 12009-12018 (2006).
133. Altucci, L. et al. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res. 65, 8754-8765 (2005).
134. Crowe, D. L. & Chandraratna, R. A. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res. 6, R546-R555 (2004).
135. Bischoff, E. D., Gottardis, M. M., Moon, T. E., Heyman, R. A. & Lamph, W. W. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res. 58, 479-484 (1998). A striking example of the potency of rexinoids for control of breast cancer.
136. Agarwal, V. R., Bischoff, E. D., Hermann, T. & Lamph, W. W. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin). Cancer Res. 60, 6033-6038 (2000).
137. Suh, N. et al. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin. Cancer Res. 8, 3270-3275 (2002).
138. Esteva, F. J. et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J. Clin. Oncol. 21, 999-1006 (2003).
139. Khuri, F. R. et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 19, 2626-2637 (2001).
140. Sporn, M. B. Dichotomies in cancer research: some suggestions for a new synthesis. Nature Clin. Pract. Oncol. 3, 364-373 (2006).
141. Bischoff, E. D., Heyman, R. A. & Lamph, W. W. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J. Natl Cancer Inst. 91, 2118 (1999).
142. Wu, K. et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol. Biomarkers. Prev. 11, 467-474 (2002).
143. Suh, N. et al. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin. Cancer Res. 8, 3270-3275 (2002). The first report of the combination of a rexinoid and a SERM for prevention and treatment of breast cancer.
144. Wu, K. et al. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 62, 6376-6380 (2002). The first report of the use of a rexinoid to prevent ER-negative breast cancer.
145. Yen, W. C., Prudente, R. Y. & Lamph, W. W. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res. Treat. 88, 141-148 (2004).
146. Lubet, R. A. et al. Efficacy of Targretin on methylnitrosourea- induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. Carcinogenesis 26, 441-448 (2005).
147. Liby, K. et al. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin. Cancer Res. 12, 5902-5909 (2006).
148. Hermann, T. W. et al. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer 50, 9-18 (2005).
149. Wang, Y. et al. Prevention of lung cancer progression by bexarotene in mouse models. Oncogene 25, 1329 (2006).
150. Yen, W. C., Prudente, R. Y., Corpuz, M. R., Negro-Vilar, A. & Lamph, W. W. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br. J. Cancer 94, 654-660 (2006).
151. Pereira, M. A. et al. Prevention of mouse lung tumors by targretin. Int J Cancer 118, 2359-2362 (2006).
152. Yen, W. C. & Lamph, W. W. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer. Prostate 66, 305-316 (2006).
153. Cesario, R. M. et al. The rexinoid LG100754 is a novel RXR:PPARγ agonist and decreases glucose levels in vivo. Mol. Endocrinol. 15, 1360-1369 (2001).
154. Smith, C. L. & O'Malley, B. W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25, 45-71 (2004).
155. Yen, W. C. & Lamph, W. W. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol. Cancer Ther. 4, 824-834 (2005).
156. Barabasi, A. Linked: How everything is connected to everything else and what it means (Penguin Group, New York, 2000).
157. Bouwmeester, T. et al. A physical and functional map of the human TNF-α/NF-κ B signal transduction pathway. Nat Cell Biol 6, 97-105 (2004).
158. Juan, M. E., Wenzel, U., Ruiz-Gutierrez, V., Daniel, H. & Planas, J. M. Olive fruit extracts inhibit proliferation and induce apoptosis in HT-29 human colon cancer cells. J. Nutr. 136, 2553-2557 (2006).
159. Mix, K. S. et al. A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum. 44, 1096-1104 (2001).
160. Elliott, S., Hays, E., Mayor, M., Sporn, M. & Vincenti, M. The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes. Arthritis Res. Ther. 5, R285-R291 (2003).
161. Yates, M. S. et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol. Cancer Ther. 6, 154-162 (2007).
162. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
163. Benoist, C. & Mathis, D. Mast cells in autoimmune disease. Nature 420, 875-878 (2002).
164. Weiner, H. L. & Selkoe, D. J. Inflammation and therapeutic vaccination in CNS diseases. Nature 420, 879-884 (2002).
165. Cohen, J. The immunopathogenesis of sepsis. Nature 420, 885-891 (2002).
166. Rangasamy, T. et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest. 114, 1248-1259 (2004).
167. Rangasamy, T. et al. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J. Exp. Med. 202, 47-59 (2005).
168. Thimmulappa, R. K. et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J. Clin. Invest. 116, 984-995 (2006).
169. Burton, N. C., Kensler, T. W. & Guilarte, T. R. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 27, 1100 (2006).
170. Honda, T. et al. Design, synthesis, and antiinflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. Bioorg. Med. Chem. Lett. 16, 6306-6309 (2006).